Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Exosomes & Liquid Biopsies Europe 2018

Valérie Taly's Biography



Valérie Taly, CNRS Research Director, Professor and Group leader Translational Research and Microfluidics, Université Paris Cité

V. Taly is a CNRS research director and group leader of the Translational Research And Microfluidics team within the clinical oncology research unit MEPPOT (personalized medicine pharmacogenomics and therapeutic optimization) in the Cordeliers Research Center (university Paris Cité). Her team performs interdisciplinary researches aiming at developing and validating microfluidic tools for cancer research in close collaboration with clinicians and researchers in oncology and toxicology. Since 2008, she developed droplet-based digital procedures for Cancer diagnosis. Recently, her research has been dedicated to the clinical validation of droplet-based microfluidics for the non-invasive detection of Cancer biomarkers, the highlighting of new Cancer Biomarkers and the development of original tools and procedures for their detection with applications in personalized medicine, cancer recurrence detection and cancer diagnostics. She is co-founder of EMULSEO (2018) and METHYS DX (2021) start up companies.

Valérie Taly Image

Droplet-Based Digital PCR Procedures and Optimized NGS to Track Circulating Tumor DNA in Liquid Biopsies: Application to Cancer Patient Follow-Up

Thursday, 25 October 2018 at 15:00

Add to Calendar ▼2018-10-25 15:00:002018-10-25 16:00:00Europe/LondonDroplet-Based Digital PCR Procedures and Optimized NGS to Track Circulating Tumor DNA in Liquid Biopsies: Application to Cancer Patient Follow-UpExosomes and Liquid Biopsies Europe 2018 in Rotterdam, The NetherlandsRotterdam, The NetherlandsSELECTBIOenquiries@selectbiosciences.com

Tracking of circulating cell-free nucleic acids in body effluents has been greatly facilitated by recent technological developments including droplet-based digital PCR and optimized NGS. In particular, droplet based digital PCR has allowed to reach unprecedented sensitivity and accuracy for rare sequences detection. Complementarity of these technologies will be presented through several retrospective and prospective studies. Moreover, we will present their application for the detection of circulating tumor DNA and its potential use for cancer patient treatment management.


Add to Calendar ▼2018-10-24 00:00:002018-10-26 00:00:00Europe/LondonExosomes and Liquid Biopsies Europe 2018Exosomes and Liquid Biopsies Europe 2018 in Rotterdam, The NetherlandsRotterdam, The NetherlandsSELECTBIOenquiries@selectbiosciences.com